News | Cardiovascular Clinical Studies | July 15, 2022

Molecular Heart Mapping and Cripsr Technology Create New Possibilities for Health Science

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG
 

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG

Image courtesy of MMRI


July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details of the heart at the cellular level. What if we could zoom in even further, via single nucleus profiling, to peer inside the heart with a molecular view? Imagine the incredible possibilities of such a detailed map: With this knowledge, doctors will be better able to diagnose and treat diseases of the heart and cardiovascular system.    

This is precisely what a team of 19 scientists are determined to learn, in a new peer-reviewed study published in the science journal, Nature. The study, titled, “Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy,” identified molecular alterations in failing hearts at single-cell resolution, by performing single-nucleus RNA sequencing of nearly 600,000 nuclei. This is truly a story of how a “small view” can have “big possibilities.”   

The team was led by Patrick T. Ellinor, MD, PhD an Institute Member at the Broad Institute of MIT and Harvard and a cardiologist in the Demoulas Center for Cardiac Arrhythmias at the Massachusetts General Hospital Heart Center. Dr. Ellinor’s team included scientists from the Precision Cardiology Lab (PCL) of the Broad Institute of MIT and Harvard and Bayer, AG and MMRI.    

Dr. Nathan Tucker of Masonic Medical Research Institute was a driving force behind the initiation of the study when he was at Broad, and he continued to contribute to the study from his lab in Utica, New York. “We often think of hearts solely as muscles, but they are actually a complex mixture of cells that need to work together in order to perform its function as a pump,” said Dr. Tucker, regarding the new study. “In the past, we have not been able to look at these other critical components, but through revolutionary technology such as we use here, our ability to accurately examine these other cells is unlocked. In this study, using this technology and a series of human tissue samples, we identified novel state transitions in end stage heart failure at single cell resolution. It is our hope to use these new targets as the basis for therapeutic development in the future.”  

The ground-breaking effort builds upon Dr. Tucker’s already extensive work on heart mapping. In 2020, Dr. Tucker led a team to create a cell map of the human heart, the most comprehensive to date, stating, “Understanding of human cardiac biology at this resolution was not possible just a few years ago."  

For more information: www.MMRI.edu 


Related Content

News | Heart Failure

May 22, 2024 — New research from The Cooper Institute and partners at University of Texas (UT) Southwestern Medical ...

Home May 22, 2024
Home
News | Heart Failure

April 30, 2024 — A multicenter study led by Vanderbilt University Medical Center (VUMC) and Lipscomb University College ...

Home April 30, 2024
Home
News | Heart Failure

April 16, 2024 — Each year more than 500,000 Americans undergo percutaneous coronary intervention, or PCI, a minimally ...

Home April 16, 2024
Home
News | Heart Failure

April 12, 2024 — University of Virginia School of Medicine researchers have discovered a gene on the Y chromosome that ...

Home April 12, 2024
Home
News | Heart Failure

April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those ...

Home April 02, 2024
Home
News | Heart Failure

March 29, 2024 — V-Wave announced it will present late-breaking data from its RELIEVE-HF pivotal trial at the American ...

Home March 29, 2024
Home
News | Heart Failure

March 25, 2024 — A team of engineers led by the University of Massachusetts Amherst and including colleagues from the ...

Home March 25, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
News | Heart Failure

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
News | Heart Failure

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
Subscribe Now